Network-based multivariate gene-set testing by Städler, Nicolas & Mukherjee, Sach
ar
X
iv
:1
30
8.
27
71
v1
  [
sta
t.M
E]
  1
3 A
ug
 20
13
Network-based multivariate gene-set testing
Nicolas Sta¨dler
Netherlands Cancer Institute
Amsterdam, Netherlands.
n.stadler@nki.nl
Sach Mukherjee
Netherlands Cancer Institute
Amsterdam, Netherlands.
s.mukherjee@nki.nl
Abstract
The identification of predefined groups of genes (“gene-sets”) which are differen-
tially expressed between two conditions (“gene-set analysis”, or GSA) is a very popular
analysis in bioinformatics. GSA incorporates biological knowledge by aggregating over
genes that are believed to be functionally related. This can enhance statistical power
over analyses that consider only one gene at a time. However, currently available GSA
approaches are all based on univariate two-sample comparison of single genes. This
means that they cannot test for differences in covariance structure between the two
conditions. Yet interplay between genes is a central aspect of biological investigation
and it is likely that such interplay may differ between conditions. This paper proposes
a novel approach for gene-set analysis that allows for truly multivariate hypotheses, in
particular differences in gene-gene networks between conditions. Testing hypotheses
concerning networks is challenging due the nature of the underlying estimation prob-
lem. Our starting point is a recent, general approach for high-dimensional two-sample
testing. We refine the approach and show how it can be used to perform multivariate,
network-based gene-set testing. We validate the approach in simulated examples and
show results using high-throughput data from several studies in cancer biology.
Keywords Gene-set testing, Gaussian graphical models, Differential network,
Graphical Lasso, Cancer biology
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1 Introduction
Differential expression analysis (Tusher et al., 2001; Lo¨nnstedt and Speed, 2002; Smyth,
2004) is one of the most popular statistical analyses in molecular biology, whether for
mRNA (including RNA-seq and microarrays), protein or epigenomic data. For each vari-
able (or gene, we use both terms interchangeably throughout but note that methods
described apply also to other types of data) expression levels are compared between con-
ditions of interest to obtain a measure of significance for the gene, usually accounting for
multiple comparisons.
Subramanian et al. (2005) pointed out a number of drawbacks of classical, single gene
differential expression analysis, including lack of statistical power and difficulties in in-
terpreting significant genes in a biological context. They addressed these concerns by an
approach called gene-set analysis or GSA which sought to test differential expression not
at the level of single genes in isolation, but rather using (pre-defined) groups of biologically
related genes called gene-sets. GSA can provide gains in power by taking advantage of the
biological knowledge encoded in gene-set membership: for example, if several members of
a certain gene-set all show a moderate change between conditions, the gene-set as whole
may be significant even if its constituent genes would not be significant on a gene-by-gene
basis. Furthermore, by providing results at the level of biologically meaningful sets of
genes, GSA can aid in interpretation of the results of differential expression analysis. GSA
has become one of the most widely used analyses in bioinformatics. Irizarry et al. (2009)
provide a self-contained introduction to GSA aimed at a statistical audience; GSA and ex-
tensions thereof are further described in Subramanian et al. (2005); Efron and Tibshirani
(2007); Jiang and Gentleman (2007).
GSA focuses on multiple genes taken together. However, existing GSA approaches (Subramanian et al.,
2005; Irizarry et al., 2009; Efron and Tibshirani, 2007) are based on univariate statistics
comparing the two conditions of interest. That is, they aggregate several single-gene
comparisons to arrive at a gene-set-level statistic and measure of significance. In these
procedures, for each gene j = 1, . . . , p a two-sample statistic zj is computed. The zj ’s
for genes belonging to specific gene-sets As, s = 1, . . . , S are then combined to arrive at
aggregate scores as at the gene-set-level. Despite the usefulness of these approaches they
have a major limitation in that they are all based on single-gene comparisons and are
therefore inherently univariate in nature. In particular, changes in covariance structure
between two conditions cannot be tested by such approaches. However, interplay between
molecular variables is a fundamental aspect of biology and it is likely that in many settings
differences in covariance or conditional independence structure between conditions may
be relevant. These observations motivate a need to extend classical GSA in a multivariate
direction.
This article is about extending GSA to allow assessment of the importance or significance
of gene-sets via multivariate statistics. As we describe below, the approach we propose
can be interpreted as testing for differences between conditions at the level of networks.
To describe gene-gene networks we use graphical models in which the absence/presence of
edges corresponds to conditional independence statements. The method we propose for
multivariate, network-based gene-set testing is called NetGSA. For each gene-set, NetGSA
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carries out a multivariate, network-based comparison between conditions (details are out-
lined below), adjusts the obtained p-values for multiple comparison and finally provides a
list of gene-sets ordered by significance. The results of NetGSA (focusing on differences
at the network level) can also be combined with those obtained from “classical” GSA to
determine significance in terms of both networks and change in average gene expression.
Network-based gene-set analysis is challenging. It requires two-sample comparison between
networks for typically hundreds of gene-sets and involves issues of high-dimensionality
and multiplicity. The intention is not to compare two known networks, but rather to
test significance of differences between two estimated networks. High-dimensionality poses
severe challenges in this setting since the number of samples is typically small compared to
the large parameter spaces required for describing the networks. This makes estimation of
graphical model structure (“network inference”) a challenging problem, and the difficulties
are inherited in the case of two-sample comparison of estimated networks.
The proposed approach for gene-set testing is based on recently developed methodology
for high-dimensional two-sample testing described in Sta¨dler and Mukherjee (2013) and
in particular on an approach called differential network or DiffNet which quantifies the
difference between two networks inferred from different populations by a p-value. DiffNet is
based on the sample splitting technique introduced by Wasserman and Roeder (2009): the
data is randomly split into two halves, networks are inferred on one half and significance
testing (p-value calculation) is performed on the other half. This process is repeated many
times in order to prevent a “p-value lottery” due to the arbitrary choice of the data split
(Meinshausen et al., 2009).
To the best of our knowledge, DiffNet is currently the only available approach that allows
two-sample testing in high-dimensional graphical models. Note, that permutation-based
tests are computationally not feasible here as a large number of permutations would be
necessary to compensate the multiple testing correction. We restrict attention to mul-
tivariate comparisons at the gene-set level; that is, we test networks whose nodes are
identified with members of gene-sets, and whose edges are within rather than between
gene-sets. The general approach of Sta¨dler and Mukherjee (2013) could in principle be
applied to comparison of full, p-dimensional distributions or networks between conditions,
but this is a very difficult high-dimensional problem and is beyond the scope of this paper.
The approach we propose can in principle be used with any graphical model formulation.
However, for NetGSA network analyses have to be conducted for each gene-set. There are
typically hundreds of gene-sets and the number genes per gene-set can vary from a few up
to several dozens of genes. Thus, network inference (NI) approaches used in DiffNet have
to be computationally efficient, and chosen and tuned carefully. They need to be able
to deal automatically with different numbers of nodes (genes), they have to satisfy two
conditions related to potential overfitting (screening and sparsity assumptions). We focus
on Gaussian graphical models (GGMs) and compare a number of specific approaches for
their estimation. The overall procedure we propose is computationally efficient and naively
parallelizable: for analysis of a lung cancer gene expression dataset reported below, with
d = 1208 genes and S = 216 gene-sets, computation required 52 minutes on a multicore
system using 50 cores (each 1.5 GHz) and 504 GB shared memory.
3
Section 2 introduces our main methodology for network-based gene-set testing: Section 2.1
formulates the hypothesis testing problem; Section 2.2 expands on DiffNet (Sta¨dler and Mukherjee,
2013); Section 2.3 describes our novel algorithm NetGSA; Section 2.4 discusses different
network inference (NI) approaches. In Section 3 we report on simulation results and real
data examples from cancer biology are investigated in Section 4.
2 Methods
2.1 Notation and set-up
Let X and Y be matrices of gene expression levels obtained under two conditions. The
dimension of X, Y are nx × d and ny × d respectively, where d denotes the total number
of genes under study and nx and ny are the condition-specific sample sizes (throughout
we use x and y to denote the two conditions). Gene-sets are denoted As ⊂ {1, . . . , d},
s = 1, . . . , S; gene-sets need not be disjoint. We denote the probability density function of
genes belonging to set As by f
x
s and f
y
s for conditions x and y respectively; these densities
are joint over all genes belonging to the gene-set and accordingly have dimension ds, where
ds = |As|.
For a specific gene-set As, our aim is to test whether or not the two conditions have different
graphical model or network structure. We use Gaussian graphical models (GGM) to model
condition-specific conditional independence structure. Vertices in the graphical models
for gene-set As are identified with members of the gene-set and edges with conditional
independence statements between them. We first present NetGSA focusing on testing
network differences only and do not test also for differences in the mean; we therefore
assume the Gaussian distributions fxs and f
y
s have identical, zero mean but potentially non-
identical concentration matrices denoted by Ωxs and Ω
y
s respectively. The edge structure
or network of the corresponding graphical models are defined by
(Ωxs)j,j′ = 0⇔ (j, j
′) /∈ E(Gxs ) and (Ω
y
s)j,j′ = 0⇔ (j, j
′) /∈ E(Gys)
where Gxs and G
y
s are undirected graphs associated with the condition-specific graphical
models and E(G) denotes the edge set of graph G.
Thus, for gene-set As, the NetGSA null hypothesis is
H0,s : Ω
x
s = Ω
y
s . (2.1)
To test these hypotheses, our strategy is to use Differential Network (described in Sec-
tion 2.2) to test each gene-set separately and then correct the obtained p-values for multiple
testing. Note that gene-sets contain different numbers of genes which can vary from mod-
erate to very large. As the sample sizes nx and ny are typically small, testing (2.1) is
challenging and involves issues of high-dimensionality.
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2.2 Differential networks
We recently developed a novel and very general approach for high-dimensional two-sample
testing (Sta¨dler and Mukherjee, 2013). We also outlined how to use the approach for
two-sample comparison of graphical models (differential network or DiffNet). In this
Section we review DiffNet with reference to the NetGSA context; we refer the reader to
Sta¨dler and Mukherjee (2013) for further technical details.
2.2.1 Network testing using sample splitting
Consider a gene-set As and corresponding gene expression matrices Xs and Ys for the two
conditions (of size nx×ds and ny×ds respectively). For each condition, we randomly split
the data into two halves Xs = (X
in
s ,X
out
s ) and Ys = (Y
in
s ,Y
out
s ). To test the hypothesis
H0,s : Ω
x
s = Ω
y
s , DiffNet proceed in two steps:
1. Network screening step. Based on the first half of the data, Xins and Y
in
s , networks
Gˆxs and Gˆ
y
s are estimated for each condition separately. In addition, a third network
Gˆxys is built using pooled data (Xins ,Y
in
s ). The latter network should provide a
good model in the null case of no difference between the two conditions. Under the
alternative, however, modeling both conditions with different graphs Gˆxs and Gˆ
y
s is
beneficial. We propose and compare several ways of inferring the networks Gˆxs , Gˆ
y
s
and Gˆxys in Section 2.4.
2. P-value calculation step. The networks Gˆxs and Gˆ
y
s model each condition individually
and give rise to a log-likelihood Linds = LGˆxs
+ LGˆys . On the other hand, Gˆ
xy
s models
pooled data jointly with log-likelihood Ljoints = LGˆxys . We compare the individual
with the joint model using the score
∆AICs = AIC
ind
s −AIC
joint
s (2.2)
= 2
(
Linds − L
joint
s
)
− 2(df inds − df
joint
s ),
with degrees of freedom df inds = 2ds+ |E(Gˆ
x
s )|+ |E(Gˆ
y
s)| and df
joint
s = ds+ |E(Gˆ
xy
s )|.
This score is based on the Akaike Information Criterion (AIC). We emphasize that all
log-likelihoods appearing in ∆AICs are evaluated using the second half of the data
and involve maximum likelihood estimation with constraints given by the graphs.
If X and Y arise from different networks, then we expect ∆AICs to be larger than
zero. In fact, it can be shown that ∆AICs tends to infinity for large sample sizes.
On the other hand, under the null hypothesis, ∆AICs is asymptotically distributed
as a shifted weighted-sum-of-chi-quares with distribution function Ψ(·; ν, δ), weights
ν = (ν1, . . . , νr) and shift δ = 2(df
ind
s − df
joint
s ). As a consequence a p-value for the
hypothesis H0,s can be obtained by
ps = 1−Ψ(∆AICs; ν, δ). (2.3)
For all details, in particular on the computation of the weights ν, we refer to
Sta¨dler and Mukherjee (2013).
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2.2.2 Screening and sparsity assumptions
There are two key assumptions in the above procedure which are mandatory to obtain
correct p-values which control the type-I error. Both involve the network inference ap-
proach used in the first step of DiffNet. Consider a n× d data matrix X generated from
a GGM with graph G. Then, the estimated graph Gˆ(X) has to satisfy:
• Screening assumption (ScA). The edge set of the inferred graph contains the edge
set of the true data generating graph: E(G) ⊆ E(Gˆ).
• Sparsity assumption (SpA). The inferred networks are sparse, i.e., the number of
edges |E(Gˆ)| is not too large compared to the sample size n.
Both assumptions are important. ScA guarantees that the models involved in the test
statistic are correctly specified and that ∆AICs has asymptotic null-distribution Ψ(·; ν, δ).
SpA is necessary to ensure maximum likelihood estimation in the second split is well-
behaved and to render the asymptotic approximation of the null-distribution accurate.
2.2.3 Sparsity index
To monitor sparsity we use a sparsity index m(Gˆ) defined as:
m(Gˆ) =
2|E(Gˆ)|
n× p
. (2.4)
This quantity has a motivation in terms of linear regression: estimating the concentration
matrix of a GGM with graph G can be done by regressing each variable (or node) j
against all neighbouring variables nbj = {i : (i, j) ∈ E(G)} ⊂ {1, . . . , k}. If we assume
that neighbouring sets are of approximately the same size (|nbj| ≈ const) then the inverse
1/m(G) of the sparsity index for graph G can be interpreted as the number of samples
per predictor. In linear regression a typical rule of thumb is 5 to 10 samples per predictor
to obtain well-behaved parameter estimation. Later, we use the sparsity index m to carry
out adaptive thresholding to ensure estimation and p-value calculation in the second split
are well-behaved.
In Section 2.4 we discuss different GGM estimation procedures from the literature and
discuss their properties in terms of the screening and sparsity assumptions.
2.3 The NetGSA algorithm
By applying DiffNet to all gene-sets As, s = 1, . . . , S we get p-values p
s, s = 1, . . . , S. To
test (2.1) we then adjust these values for multiple comparison and obtain the corrected
p-values p˜s, s = 1, . . . , S. The outcome depends heavily on the initial data splitting (see
Section 2.2). Depending on the random split of the data we can get different results which
amounts to a “p-value lottery” (Meinshausen et al., 2009). To get stable and reproducible
results we therefore repeat the splitting process many times and aggregate the resulting p-
values. A simple approach combines the p-values by taking the median (van de Wiel et al.,
2009). Algorithm 1 summarizes the overall procedure which we call NetGSA.
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Algorithm 1 NetGSA: Network-based gene-set analysis
Input Data X and Y, gene-sets As, s = 1, . . . , S, number of data splits B.
1: Randomly split data into two halves
2: for s = 1, . . . , S do
3: Network Screening (on 1st half)
Using a network inference procedure, infer networks Gˆxs , Gˆ
y
s and Gˆ
xy
s .
4: P-values (on 2nd half)
Evaluate Linds = LGˆxs
+ LGˆys , L
joint
s = LGˆxys and df
ind
s , df
joint
s .
Evaluate ∆AICs = AIC
ind
s −AIC
joint
s .
Obtain ps = 1−Ψ(∆AICs; ν, δ),
where δ = 2(df inds − df
joint
s ) and ν are weights estimated following
Sta¨dler and Mukherjee (2013).
5: end for
6: Calculate FDR-corrected p-values: p˜1, . . . , p˜S .
7: Repeat steps 1-6 B times.
Output Aggregated quantities (median over B splits): p˜s,med (s = 1, . . . , S).
We point out that Algorithm 1 tests only for differences in terms of networks and does
not pick-up changes between the two conditions due to a difference in mean level. We
propose below a simple procedure for combining the results of NetGSA as described above
with standard approaches for mean-based GSA to obtain a combined gene-set test that
captures differences in networks and the mean.
2.4 Network Inference (NI) Approaches
Network inference (NI) is an important part of DiffNet. In Section 2.2 we pointed out that
NI has to be in line with ScA and SpA in order to obtain valid p-values. Besides that, NI
is the limiting factor in the overall computational complexity of Algorithm 1. Note that
three networks have to be inferred for each of the S gene-sets in each of the B data splits.
Thus, in total there are 3 × S × B networks to be estimated. We now consider different
NI approaches. The properties of DiffNet with each of these NI methods are examined in
Section 3.1.
1. Graphical Lasso (GL). The Graphical Lasso (Yuan and Lin, 2007; Friedman et al.,
2008) estimates the concentration matrix Ω by optimizing
Ωˆλ = argmin− log |Ω|+ tr(SΩ) + λ‖Ω‖1.
where S is the sample covariance matrix and λ denotes a penalty parameter. Let
G(Ωˆλ) denote the graph structure defined by the zero entries of Ωˆλ.
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The choice of λ is very important, as it determines the sparsity of the graph: too
large λ leads to a very sparse solution which is likely to be in contradiction with
ScA. On the other hand, too little regularization (small λ) results in dense networks
which conflict with SpA.
We set λ to a value λ∗ as follows. We take a sequence of twenty λ-values on the
log-scale between λmax = maxj>j′ |Sjj′| and λmin, with λmin = λmax/100 (p > n)
and λmin = λmax/1000 (p < n). Then, λ
∗ is selected by either 10-fold cross-
validation or the Bayesian information criterion (BIC) with degrees of freedom
df =
∑
j≥j′ 1Ωˆλ
jj′
6=0. Both routes aim to select λ in a prediction optimal fashion
and typically result in relatively sparse networks which overestimate the true struc-
ture but are likely to satisfy ScA.
Additionally, to ensure SpA is satisfied, we evaluate the sparsity index m(G(Ωˆλ
∗
)).
If inverse sparsity 1/m exceeds a pre-defined threshold τ , we set to zero those entries
in Ωˆλ
∗
having the smallest corresponding absolute partial correlations until 1/m ≤ τ .
In all numerical examples we use τ = 5 which is a reasonable heuristic in light of
the regression interpretation from Section 2.2.
For computations of the Graphical Lasso we use theR-package glasso (Friedman et al.,
2008). We note that BIC is computationally more efficient than cross-validation.
2. Meinshausen-Bu¨hlmann (MB). The Meinshausen-Bu¨hlmann approach estimates a
sparse graphical model by fitting a lasso model to each variable, using the others as
predictors (Meinshausen and Bu¨hlmann, 2006; Tibshirani, 1996). The graph struc-
ture is given by the non-zero entries of the estimated regression coefficients. We take
for all Lasso regressions the same tuning parameter λ which we determine by 10-
fold cross-validation on a λ-grid as described above. The MB approach has similar
properties as the Graphical Lasso. In our examples, however, we found that the MB
approach results in sparser graphs.
MB is performed using the function glasso (R-package glasso) with the option
approx=TRUE.
3. Shrinkage Estimation (Shrink). We further consider the approach proposed by
Scha¨fer and Strimmer (2005) based on shrinkage estimation of the covariance matrix
and subsequently testing for non-zero partial correlation coefficients. This approach
is computationally very simple. The shrinkage level can be obtained analytically
following Ledoit and Wolf (2004) and there is no need for CPU expensive tuning
parameter selection, e.g., cross-validation. Testing for non-zero partial correlation
coefficients involves FDR correction. However, it is known (Kra¨mer et al., 2010)
that the inferred networks systematically underestimate the number of edges in the
true graph. Therefore, despite its computational advantages, it is interesting to
investigate whether Shrink can be used in step 1 of DiffNet.
We use the R-package parcor (Kra¨mer et al., 2010) with the default FDR cut-off
0.8 to compute networks based on the shrinkage estimator.
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3 Simulations
Ability to compare networks is crucial to NetGSA. We therefore begin in Section 3.1 by
comparing the different NI methods from Section 2.4 in terms of their performance in
testing network differences. In the following Section 3.2 we consider gene-set simulations
to test NetGSA itself.
3.1 Comparison of different network inference approaches
To compare NI methods, we generate data from the following models:
Model 1 Draw data for the two conditions x and y from a d-dimensional multivariate
normal distribution with nx = ny = 100 and d = 50. The inverse covariance matrices
Ωx and Ωy each have 10 non-zero entries at random locations of which 10 × α are
at the same position in Ωx and Ωy. We take α = 0.7, 0.8, 0.9 and 1, where α = 1
represents the H0 scenario. Generated data are scaled and centered to have zero
mean and variance one.
Model 2 Draw both populations according to a d-dimensional multivariate normal dis-
tribution with nx = ny = 100, d = 50 and 1st order autoregressive covariance
matrices. In particular, we take (Σx)jj′ = 0.7
|j−j′| and (Σy)jj′ = β
|j−j′| with
β = 0.7, 0.76, 0.78, 0.8. Then, the choice β = 0.7 corresponds to the H0 assump-
tion. Generated data are scaled and centered to have zero mean and variance one.
For each of these models we performed 250 simulation runs. In each run we carried out a
DiffNet analysis using the NI approaches summarized in Table 1. We report the propor-
tion of rejected null-hypothesis (power function), the number of times ScA is satisfied,
the relative number of nonzero elements in the inverse covariance matrices (sparsity index,
see equation (2.4) of Section 2.2) and the CPU time1. We further add as a reference the
performance of two “classical” two-sample likelihood-ratio tests (LRTs) where the first
is based on maximum likelihood estimation with unrestricted covariance matrices (LRT,
asymptotic χ2d×(d+1)/2 null-distribution) and the second assumes diagonal covariance ma-
trices (LRT-diag, asymptotic χ2d null-distribution). All results are shown in Figures 1
and 2.
For Model 1, we find thatGL andMB approaches control the type-I error at the 5%-level.
They are also comparable in terms of power. As expected, selecting λ∗ with BIC is about
10 times faster then cross-validation. Interestingly, the shrinkage approach Shrink has
type-I error control despite of frequent model misspecification in step 1 of DiffNet (ScA
holds in only 30% of the simulation runs satisfied). Nevertheless, Shrink performs worse
in terms of power.
From the results for Model 2 we see that CV and also BIC show too many false rejections
which can be explained by a larger sparsity index. Use of the adaptive thresholding pro-
cedure we propose above (GL-CV-AT and GL-BIC-AT) is sufficient to settle the false
1This was obtained using the specific R packages mentioned above, and is therefore an implementation-
dependent measure. We did not consider formal computational complexity.
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positive rate at the desired 5%-level. In Model 2, Shrink performs badly: in about half of
the cases the null-hypothesis is wrongly rejected. Note, that the screening assumption is
satisfied in less than 10% of the cases when using Shrink. This suggests that it may not
be advisable to use Shrink for network inference in DiffNet. Finally, our reference meth-
ods, LRT and LRT-diag, behave as expected: as a consequence of small sample sizes
the asymptotic χ2d×(d+1)/2 null-distribution is a very poor approximation when computing
p-values using LRT. On the other hand the likelihood-ratio statistic used in LRT-diag
contains only information about potential differences in the diagonal of the covariance
matrices and therefore cannot detect any differences between the two conditions in the
examples here.
From the analysis of the results for both Models 1 and 2 we conclude that GL-BIC-AT is
a good choice and we use it as the default NI approach in NetGSA for all our subsequent
analyses.
Name Network inference method Tuning parameter Adaptive thresholding
GL-CV Graphical Lasso cross-validation no
GL-CV-AT Graphical Lasso cross-validation yes
GL-BIC Graphical Lasso BIC no
GL-BIC-AT Graphical Lasso BIC yes
MB-CV Meinshausen-Bu¨hlmann cross-validation no
Shrink Shrinkage covariance estimator set analytically no
Table 1: NI (network inference) approaches compared in simulation study of Section 3.1.
Key: GL, Graphical Lasso; MB, Meinshausen-Bu¨lmann approach; CV, tuning parameter
chosen by cross-validation; BIC, tuning parameter chosen by BIC; AT, use of adaptive
thresholding (see text); Shrink, shrinkage approach proposed by Scha¨fer and Strimmer
(2005) with default FDR cut-off 0.8.
3.2 Performance of NetGSA
In this study we simulate data for S = 20 gene-sets. For each gene-set s we generate data
matrices Xs and Ys from N (µ
x
s ,Σ
x
s ) and N (µ
y
s ,Σ
y
s) with n = nx = ny = 40. The number
of genes ds of gene-set s is drawn uniformly from {20, . . . , n− 1} (ds < n ensures that the
conventional LRT is well-defined). The gene-set specific means, µxs and µ
y
s , are taken to
be zero except for the first three gene-sets:
• Gene-set 1: µx1 = 0. µ
y
1j = 0.2, j = 1, . . . , d1.
• Gene-set 2: µx2 = 0. µ
y
2j = 0, j = 1, . . . , ⌈d2/2⌉ and µ
y
2j = 0.4, j = 1, . . . , ⌊d2/2⌋.
• Gene-set 3: µx3 = 0. µ
y
3j = −0.2, j = 1, . . . , ⌈d3/2⌉ and µ
y
3j = 0.2, j = 1, . . . , ⌊d3/2⌋.
• Gene-sets 4-20: µxs = µ
y
s = 0.
All gene-sets have inverse covariance matrices generated as in Model 1. We set Ωxs and
Ωys to have ⌈ds/2⌉ non-zero entries at random locations, of which αs×⌈ds/2⌉ are common
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Figure 1: Results Model 1. Performance of DiffNet with different NI approaches and
different levels of network concordance (α). First panel: Power function (proportion of
rejected null-hypothesis). Second panel: In green: proportion of times ScA is satisfied, in
blue: sparsity index. Third panel: CPU times. [The different NI methods GL-CV, GL-
CV-AT, GL-BIC, GL-BIC-AT, MB-CV and Shrink are described in Table 1. LRT:
two-sample likelihood-ratio test for difference between covariance matrices (asymptotic
χ2d×(d+1)/2 null-distribution). LRT-diag: diagonal-restricted two-sample likelihood-ratio
test (asymptotic χ2d distribution)].
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Figure 2: Results Model 2. Same caption as in Figure 1.
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across both conditions. The parameter αs controls relative network concordance and is
chosen as:
• Gene-sets 1-3: α = α1 = α2 = α3 ∈ {0, 0.25, 0.5, 1}.
• Gene-sets 4-20: αs = 1, i.e. Ω
x
s = Ω
y
s .
Gene-sets one to three exhibit a difference between conditions in terms of their means.
All gene-sets have non-trivial gene networks. By decreasing the parameter α from one to
zero we introduce additional network difference for the first three gene-sets .
The aim of this simulation is to investigate performance of NetGSA in detecting gene-sets
with network difference between x and y. We further want to investigate whether NetGSA
can improve overall performance in the setting in which conditions differ with respect to
both means and networks. For that purpose we compute p-values using NetGSA;Net(SS)
stands for the single-split approach (B = 1), Net(MS) denotes the multi-split version
(B = 50). We further run a “classical” gene-set analysis using the approach described in
Irizarry et al. (2009) (Classic) and combine NetGSA with this approach by reporting the
minimum of the two p-values (Classic+Net(MS)). Finally, we compute for each gene-set
p-values with the conventional LRT and correct them for multiple comparison (LRT).
Figure 3 shows ROC curves, averaged over 50 simulation runs, for various levels of relative
network concordance α. Table 2 shows averaged false discovery and true positive rates at
the 5% significance level. As expected performance of NetGSA improves with increasing
network difference (smaller α values). We also see that multi-splitting dominates perfor-
mance compared to using only a single data split. Testing network differences with LRT
performs poorly in all scenarios.
Calculations in NetGSA are based on Gaussian graphical models and therefore rely upon
the normality assumption. In order to investigate performance under deviations from
normality we generate data as described above but with 10% of the data contaminated
with samples from a multivariate t-distribution (degrees of freedom two and three). We
take the α = 0.25 setup and perform 50 simulation runs. Figure 4 shows ROC performance
of Net(SS), Net(MS) and LRT for the cases with and without t-contamination. As
expected performance degrades with more contamination but the effect is not dramatic
and performance of NetGSA degrades gradually. However, we also see from Table 3 that
the average false discovery rate is larger than expected in presence of t-contamination.
Therefore, we recommend to interpret results with care in case of stronger deviation from
normality as this could severely increase the number of false discoveries.
4 Applications
In this Section we apply NetGSA to three datasets from cancer biology. In each appli-
cation we compare gene expression data between two conditions, using as gene-sets the
collection from BioCarta (available at http://www.broadinstitute.org/gsea/msigdb).
The latter comprises 216 gene-sets with a number of genes per gene-set which varies from
6 to 87.
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Figure 3: Simulated data, ROC curves. ROC curves show the average true positive
rate against the average false positive rate for varying thresholds, where the rates are
with respect to gene-sets. Each panel corresponds to a different level of overlap between
condition-specific networks, as controlled by a simulation parameter α. Upper left panel
(α = 1): no network difference. Upper right panel (α = 0.5): the two networks for
gene-sets 1-3 share half of the edges. Lower left panel (α = 0.25): the two networks for
gene-sets 1-3 share a quarter of the edges. Lower right panel (α = 0): the two networks
for gene-sets 1-3 have no edges in common. [Net(SS): NetGSA with B = 1 (single-
split); Net(MS): NetGSA with B = 50 (multi-split); Classic: classic gene-set analysis
as described in Irizarry et al. (2009); Classic+Net(MS): classic gene-set analysis and
NetGSA combined; LRT: conventional likelihood-ratio test.]
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False discovery rate (false positive rate)
α = 0 α = 0.25 α = 0.5 α = 1
Classic 0 (0) 0 (0) 0.02 (0.001) 0 (0)
Classic+Net(MS) 0 (0) 0 (0) 0.005 (0.001) 0 (0)
Net(SS) 0 (0) 0 (0) 0 (0) 0 (0)
Net(MS) 0 (0) 0 (0) 0 (0) 0 (0)
LRT 0.851 (0.992) 0.849 (0.994) 0.848 (0.986) 0.848 (0.987)
True positive rate
α = 0 α = 0.25 α = 0.5 α = 1
Classic 0.08 0.113 0.087 0.107
Classic+Net(MS) 0.08 0.447 0.867 1
Net(SS) 0 0.387 0.74 0.953
Net(MS) 0 0.373 0.86 1
LRT 0.987 1 1 1
Table 2: Performance of NetGSA at the 5% significance level. Average false discovery
rate (in brackets: false positive rate) and true positive rate at the 5% significance level
for various methods and different α-values (relative network concordance of gene-set one
to three). [Net(SS): NetGSA with B = 1 (single-split); Net(MS): NetGSA with B =
50 (multi-split); Classic: classic gene-set analysis as described in Irizarry et al. (2009);
Classic+Net(MS): classic gene-set analysis and NetGSA combined; LRT: conventional
likelihood-ratio test.]
False discovery rate (false positive rate)
mvn mvt (df=3) mvt (df=2)
Net(SS) 0 (0) 0.091 (0.02) 0.299 (0.068)
Net(MS) 0 (0) 0.036 (0.007) 0.17 (0.04)
LRT 0.848 (0.986) 0.85 (0.998) 0.85 (1)
True positive rate
mvn mvt (df=3) mvt (df=2)
Net(SS) 0.74 0.76 0.74
Net(MS) 0.86 0.873 0.873
LRT 1 1 1
Table 3: Effect of t-contamination on performance of NetGSA at the 5% significance level.
Average false discovery rate (in brackets: false positive rate) and true positive rate at
the 5% significance level for different levels of t-contamination. mvn: multivariate normal
data (no contamination), mvt (df=3): 10% of the data contaminated with samples from
a multivariate t-distribution with degrees of freedom df=3, mvt (df=2): 10% of the data
contaminated with samples from a multivariate t-distribution with degrees of freedom
df=2. [Net(SS): NetGSA with B = 1 (single-split); Net(MS): NetGSA with B = 50
(multi-split); LRT: conventional likelihood-ratio test.]
Cancer cell line encyclopaedia (CCLE) We consider the dataset from the Broad-
Novartis Cancer Cell Line Encyclopedia (CCLE) (Barretina et al. (2012)2). Apart
2http://www.broadinstitute.org/ccle
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Figure 4: Effect of t-contamination on performance of NetGSA. ROC curves plot the
average true positive rate against the average false positive rate for varying thresholds.
Solid lines: multivariate normal data (no contamination). Dashed lines: t-contaminated
data with degree of freedom df=3. Dotted lines: performance for t-contaminated data
with degree of freedom df=2. [Net(SS): NetGSA with B = 1 (single-split); Net(MS):
NetGSA with B = 50 (multi-split); LRT: conventional likelihood-ratio test.]
from gene expression levels the CCLE dataset contains also anticancer drug sensitiv-
ity measurements. We consider the drug Irinotecan. We focus on the activity area
(AA) and extract the numbers of cell lines, nT and nB, in the top and bottom third
of the AA range. We then define resistant and sensitive cell lines by considering the
top nx = min{nT, nB} scoring cell lines and the bottom ny = min{nT, nB} cell lines
(with respect to AA). We compare the resistant against the sensitive cell lines.
Lung cancer We consider gene expression measurements from large airway epithelial
cells sampled from nx = 97 patients with lung cancer and ny = 90 controls (Spira et al.,
2007). This data was previously analysed with the joint graphical Lasso in Danaher et al.
(2013) and it is publicly available at GEO accession number GSE4115. We compare
the lung cancer samples against the controls.
Breast cancer The dataset by Loi et al. (2008) has gene expressions from 255 ER+
breast cancer patients treated with tamoxifen. Using distant metastasis free survival
as a primary endpoint, nx = 68 patients from this dataset are labeled as resistant to
tamoxifen and ny = 187 are labeled as sensitive to tamoxifen and we are interested
in differences between these two groups. This dataset is available at GEO accession
number GSE6532 and was analysed using the graph-structured tests for differential
expression proposed by Jacob et al. (2012).
Our novel approach, NetGSA, is based on the normality assumption. Strong violation
from normality can result in a inflated false discovery rate. We therefore conduct Shapiro-
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Wilk tests for each gene in each condition and discard genes with a p-value (corrected
for multiplicity) smaller than 1% in either of the two populations. We run the multi-split
version of NetGSA with B = 50 (Net(MS)) on all three examples, where we normalized
the input matrices X and Y to have zero mean and variance one. In addition to Net-
GSA we perform classical GSA (Classic, Irizarry et al. (2009)) on unnormalized data. In
all analyses we excluded gene-sets with ds < 5. Figures 5-7 shows scatter plots of the
negative log-p-values obtained with Net(MS) and Classic for the CCLE, the lung can-
cer and the breast cancer examples. Net(MS) identifies fewer significant gene-sets than
Classic. Interestingly, the ordering of gene-sets according to p-values differs substantially
for NetGSA and classical GSA. For example in the lung cancer study there are several
gene-sets significant under Net(MS) but not under Classic. In order to check that the
significant gene-sets are not false positives we perform “back-testing”: in particular we
pool data from both populations, randomly divide the data into two populations and then
run NetGSA with only the significant gene-sets. We repeat this process ten times. In all
examples “back-testing” never declares a gene-set as significant.
In Figures 8 and 10 we show the networks (medians of absolute partial correlation coef-
ficients over 50 random data splits) and a histogram of single-split p-values over the fifty
random splits for the top scoring gene-set in each of the three examples.
5 Discussion
The network based gene-set analysis (GSA) procedure we proposed extends gene-set anal-
ysis in a multivariate direction. We considered a number of network inference (NI) ap-
proaches and on the basis of empirical results and computational considerations suggested
the use of Graphical Lasso with adaptive thresholding and tuning parameter set using
BIC (“GL-BIC-AT”; see Table 1).
The multivariate nature of our test comes at added computational cost; our approach
is far more computationally demanding that a classical, mean-based GSA. Nevertheless,
due to the computational efficiency of Graphical Lasso, simplicity of BIC-based setting
of the tuning parameters and parallelizability, overall the analysis we propose is efficient
and practical on a multicore system. For example, a problem with with d = 1208 genes
and S = 216 gene-sets took 52 minutes of compute time using 50 cores. We used GGMs
to model and test for differences in network structure. However, the high-dimensional
two-sample test in Sta¨dler and Mukherjee (2013) is very general and NetGSA could be
extended to use other graphical models. In particular, directed edges can be appropriate in
many biological applications, and extension to the case of directed acyclic graphs (DAGs)
would be an interesting avenue for future work. Any such extension would have to carefully
consider computational demands, since as discussed above NetGSA requires many rounds
of network estimation (albeit far fewer than a naive, permutation alternative).
All our examples considered static (i.e. non-time-varying) data. In many biological ap-
plications, time course data play an important role. NetGSA could be used to compare
time-course data between conditions by use of a suitable graphical model formulation,
such as dynamic Bayesian networks or DBNs (Husmeier, 2003). In the case of (a cer-
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tain class of) DBNs computationally efficient estimation is possible (Hill et al., 2012), and
these models could therefore provide a good starting point for exploring extensions of
NetGSA to time-course data. Such a dynamic variant of NetGSA would allow testing of
differences between gene-sets based on networks estimated from time course data, and to
the extent that time-varying data contain additional information such an approach could
offer improved ability to detect biologically relevant differences. Naturally, for such an ap-
plication sufficient replicates per condition would be needed to obtain p-values, especially
via sample splitting.
In principle, given sufficiently many samples, network-based testing could be extended
beyond the gene-set level to compare networks over all d variables between conditions. In
such a set up gene-sets could be used to constrain estimation of the global network, e.g.
allowing more edges within gene-sets than between them. Testing could focus on equality
of the overall network, or of subnetworks. NetGSA as proposed here could be regarded
as a simplified version of this more general test, in which only within-gene-set edges are
allowed.
We considered only gene expression data. However, the methodology could be applied to
essentially any molecular data type (including protein and epigenetic), provided suitable
sets of variables analogous to gene-sets could be provided. In the case of proteomic data,
for example, this could allow testing of differences in protein-protein interplay within
known pathways and between conditions.
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Figure 5: P-value scatter-plots. CCLE dataset, Irinotecan-resistant against -sensitive cell
lines. The negative log-p-values obtained using NetGSA and classical GSA are plotted
against each other. In green: significant gene-sets using classical GSA; in red: significant
gene-sets using NetGSA. At 10% significance level.
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Figure 8: Networks and distribution of single-split p-values. Left and middle panels show
heatmaps of the absolute partial correlation coefficients (median over 50 random data
splits) of the top gene-set IL3 PATHWAY for the CCLE (Irinotecan) example. The right
panel shows a histogram of the single-split NetGSA p-values for gene-set IL3 PATHWAY
over the 50 random splits.
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Figure 9: Networks and distribution of single-split p-values. Left and middle panels show
heatmaps of the absolute partial correlation coefficients (median over 50 random data
splits) of the top gene-set SHH PATHWAY for the lung cancer example. The right panel
shows a histogram of the single-split NetGSA p-values for gene-set SHH PATHWAY over
the 50 random splits.
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Figure 10: Networks and distribution of single-split p-values. Left and middle panels
show heatmaps of the absolute partial correlation coefficients (median over 50 random
data splits) of the top gene-set IL7 PATHWAY for the breast cancer example. The right
panel shows a histogram of the single-split NetGSA p-values for gene-set IL7 PATHWAY
over the 50 random splits.
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